An interventional study of External, lower limb sensory prosthesis in Peripheral Neuropathy With Type 2 Diabetes, Peripheral Neuropathy Grade 2 or Greater and Balance, sponsored by RxFunction Inc.. Recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by RxFunction Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Mobility Limitation with a site in United States — 31 open to participants now, 35 under way, 3 of them phase 3. Mobility Limitation · United States.
Among the 126 studies in Mobility Limitation with a site in United States, this one is the 96th largest by planned enrollment of the 116 interventional ones that give a count, is one of 10 that started in 2026, is one of 93 with no phase, reaches primary completion later than 13 of the 34 other live ones, and was the 123rd registered.
383 studies on the registry are indexed under Mobility Limitation; 106 are open to participants now.
Browse Mobility Limitation studies →31 of the 126 studies in Mobility Limitation with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages 5–20 · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18+
The University of Alabama in Huntsville · Sites in United States
Ages 65+ · Healthy volunteers
University of Florida · Sites in United States
Ages 65–90
Northwestern University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 65 Mobility Limitation studies recruiting now, 33 (51%) set no upper age limit and 15 (23%) stop at 75 or younger; 5 take children under 18; 9 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 9
First in 1997; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 46 across 318 interventional studies indexed under Mobility Limitation.
Median enrollment 40 across the 116 interventional studies, 92 across the 10 observational. Of the 83 that completed or were terminated, 30 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 126 have an industry lead sponsor. The 10 most frequent:
RxFunction Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
RxFunction Inc. has 2 studies filed under Mobility Limitation — fewer than ten, so there is no comparison to draw.
13 of the studies in Mobility Limitation with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125378University of FloridaLiving Independence Through Functional Training | 2026-11-30 |
| NCT05725564Milton S. Hershey Medical CenterTesting Interventions for Mobility Through Exercise (TIME) | 2026-12 |
| NCT06484244Emory UniversityLocomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease | 2026-12-31 |
| NCT05661084Hebrew SeniorLifeNon-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia | 2026-12-31 |
| NCT07337317The University of Alabama in HuntsvilleEvaluating Stairway Designs for Individuals With Vision Impairment | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 126 studies in Mobility Limitation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate whether sensory stimulations from a neuroprosthesis device (Walkasins®) can increase physical activity and improve gait quality in persons with peripheral neuropathy (PN). The main question it aims to answer is whether Walkasins enhances habitual activity patterns in adults with peripheral neuropathy.
Participants will do the following as part of the study:
This will be a prospective within-participant study design conducted over a period of one year. After providing informed consent, all participants will undergo a battery of instrumented mobility assessments (e.g., 6-minute walk test [6MWT], Functional Gait Assessment [FGA], etc.), questionnaires, and a 10-day habitual physical activity observation period, wearing an electronic event logger to derive the primary outcomes. This initial (baseline) assessment, without the sensory assistance of the Walkasins, will allow participants to serve as their own control. Assessment and observation periods will be repeated at the dispensing of the Walkasins device and after participants have acclimated to daily use, 10 weeks after participants have begun wearing the device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
After the baseline visit and activity monitoring, users will receive Walkasins. They will use the device for 10 weeks during which they will also wear an activPAL activity monitor for ten days on at the beginning and end of their Walkasins use.
Device: External, lower limb sensory prosthesis
Walkasins is an external, lower limb sensory prosthesis intended to replace part of the nerve function used for detection and signaling of foot pressure sensation during standing and walking activities. Walkasins consist of two parts for each leg: the Haptic Module and the Receptor Sole. The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
Activity Score--Metabolic Equivalents (METs)
The Activity Score, expressed in metabolic equivalents (METs), reflects the overall intensity of physical activity performed. (One MET is defined as the energy a person uses when resting or sitting still.) Higher MET values indicate greater energy expenditure and higher levels of physical activity, while lower values suggest reduced activity intensity and increased sedentary behavior.
Time frame: Over a period of ~12 weeks
Step Count
Step count reflects the total number of steps accumulated over a given period and serves as an indicator of overall daily ambulatory activity. Lower step counts are associated with reduced physical activity levels and decreased functional mobility.
Time frame: Over a period of ~12 weeks
Total Sedentary Time
Total sedentary time reflects the individual's overall inactivity during the day. Prolonged sedentary behavior may contribute to deconditioning, decreased functional capacity, and increased risk for chronic disease.
Time frame: Over a period of ~12 weeks
6-Minute Walk Test--Phase Coordination Index (PCI)
The 6 Minute Walk Test is an exercise test used to evaluate aerobic capacity and endurance. The distance a subject walks in six minutes is the outcome by which to compare changes in performance capacity. Participants will wear sensors during the test that will allow for calculation of Phase Coordination Index (PCI) scores. A PCI score closer to zero indicates better bilateral coordination or better phase generation accuracy and/or consistency within the gait cycle.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
Activities-specific Balance Confidence (ABC) Scale
The ABC Scale is a 16-item self-report measure of an individual's confidence in their ability to maintain balance while performing various daily activities. Scores range from 0% to 100% to reflect perceived balance confidence, with lower scores indicating greater fear of falling and increased risk of mobility limitations.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
International Physical Activity Questionnaire (IPAQ) or IPAQ for Elderly Adults (IPAQ-E)
The International Physical Activity Questionnaire (IPAQ short form) can be used to obtain comparable estimates of physical activity between populations and countries. It consists of four questions that ask participants to state how much time they have spent engaged in various activities over the past 7 days. A higher score on the International Physical Activity Questionnaire (IPAQ) is better. The IPAQ measures physical activity in MET-minutes/week, where higher scores indicate greater physical activity, categorizing individuals as low, moderate, or high (3000+ MET-min/week) in terms of activity levels. (A MET \[Metabolic Equivalent of Task\] is a unit used to measure the energy expenditure and intensity of physical activities relative to resting, defined as the oxygen consumption of 3.5 mL/kg/min.)
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
PROMIS Scale v2.0 - Pain Intensity 3a
The PROMIS® Pain Intensity assessment was developed to capture the overall level of pain experienced by the individual, independent of its cause or location, allowing comparisons across patient groups and over time. It consists of three questions, rated on a scale from "No pain" to "Very severe" with higher scores indicative of greater pain intensity.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
PROMIS PROWalk
PROMIS® PROWalk is a patient-reported outcome measure assessing perceived walking-related functional limitations. It captures individuals' subjective experiences of mobility challenges with lower scores indicating greater physical function impairment. Participants rate their physical function on nine tasks, using a scale of 1 (Unable to do) to 5 (Without any difficulty).
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
PROMIS Sleep-Related Impairment (SRI) and Sleep Disturbance
PROMIS Sleep-Related Impairment assesses the daytime effects of poor or insufficient sleep, such as sleepiness, fatigue, difficulty concentrating, and reduced ability to perform daily activities, also over the past 7 days. Together, these complementary measures capture both sleep quality and the functional impact of sleep problems from the patient's perspective. PROMIS Sleep Disturbance measures perceived problems with sleep itself, including difficulty falling or staying asleep, restlessness, and overall sleep quality over the past 7 days. It reflects the individual's experience during the sleep period. Both are 8-item assessments with higher scores indicating more sleep dysfunction.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
10-Meter Walk Test
Gait speed will be measured through the 10-Meter Walk Test, timing the middle 10 meters with two meters before and after to allow for acceleration and deceleration. Participants will be instructed to walk at normal speed. Higher numbers indicate faster speeds (i.e., more meters per second).
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
2-Minute Dual-Task Walk (2MDTW)
The 2-Minute Dual-Task Walk is a measurement of endurance that assesses walking distance over two minutes while also performing a cognitive task (e.g., counting down by 7s from a given number). Greater distances indicate better physical functioning and mobility.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
Timed Up and Go (TUG)
The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.
Time frame: Baseline, Walkasins Initiation,
Modified Clinical Test of Sensory Interaction in Balance (mCTSIB)
The Modified Clinical Test of Sensory Interaction in Balance assesses a participant's capacity to sustain balance across four conditions to measure their postural control ability: 1) firm surface eyes open, 2) firm surface eyes closed, 3) foam surface eyes open, and 4) foam surface eyes closed. Participants will stand in each condition for 30 seconds or until they open their eyes in the eyes closed conditions or drop their hands from their hips in the eyes open conditions. Less sway, as measured by sensors, indicates better postural control.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
Single Leg Stance (SLS)
The Single Leg Stance Test (also called the unipedal stance test) "is a simple test for measuring static aspects of balance." It "is related to conditions such as peripheral neuropathy and intermittent claudication" and "is also associated with an increased risk for falls" (Springer BA, Marin R, Cyhan T, Roberts H, Gill NW. Normative values for the unipedal stance test with eyes open and closed. Journal of geriatric physical therapy. 2007 Apr 1;30(1):8-15). Participants stand unassisted on one leg with their hands on their hips. Timing begins when they lift one leg off the floor and ends when it touches the ground or the standing leg or an arm leaves the hips
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
Functional Gait Assessment (FGA)
The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability.
Time frame: Baseline, Walkasins Initiation, Follow-up (Week 10)
Monofilament Testing
The Centers for Medicare \& Medicaid Services (CMS) identifies the monofilament test as the means of diagnosing loss of protective sensation (https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=171). To conduct the test, a clinician applies pressure with various sizes of monofilament to selected parts of the foot and asks the participant to indicate when he/she feels the filament. Per CMS, inability to feel a 10-gram monofilament on at least two of five test sites on either foot indicates loss of protective sensation (LOPS). For this study participants will undergo testing on at four sites on the dominant foot with a 2g and/or 10g monofilament.
Time frame: Baseline
Plan to share: Undecided — The sponsor will make a determination on data sharing prior to publication of the results.
Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.
Of 206 interventional studies with no phase under Mobility Limitation, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RxFunction Inc.